Dr. Chin is a Harvard trained, Board Certified internist with drug development across a wide range of specialties, including oncology, immunology, ophthalmology, neurology, endocrinology, cardiovascular medicine, among others. He has been responsible for over 40 Investigational New Drug (IND) Applications and eight New Drug Applications (NDAs) / Biologic License Applications (BLAs). Some of the drugs Dr. Chin has overseen include ranibizumab , natalizumab, tenecteplase, Bapineuzumab, ziconotide, and omalizumab, He has both U.S. and international experience, and has overseen a wide variety of functions, including Clinical Development, Regulatory, Biostatistics, Quality Assurance/Compliance,… Chemistry Manufacturing and Control, Safety and Medical Affairs. Dr. Chin's is currently President and CEO of Oxigene, a biotechnology company. Previously, he was Senior Vice President and Head of Global Development for Elan Corporation, and before that served as the Head of Clinical Research for the Biotherapeutics Unit at Genentech. Dr. Chin holds a Medical Degree from Harvard Medical School. He received the equivalent of a J.D. with honors from Oxford University, England under a Rhodes Scholarship. He graduated with a Bachelor of Arts in Biology, magna cum laude, from Harvard University. He previously served on the adjunct clinical faculty at Stanford Medical School.